Summary
In the past it has been shown that antiaggregatory prostaglandins might exert an antiproliferative activity on vascular wall smooth muscle cells. This study examines this question in an experimental model and in humans as well. DCS and ACTH administration intramuscularly in rabbits causes a significant increase in the mitotic activity as measured by means of [3H] thymidine. Treatment with PGI2 is able to diminish the enhanced mitotic activity in all three vascular wall layers, whereas it does not change the mitotic activity in the control animals. After 5 days of PGE1 therapy in humans, the number of activated smooth muscle cells is decreased in the intima and in the media as well. These cells exhibit a higher PGI2-formation probably in order to counterbalance further proliferation by enhancement of intracellular cAMP. This vicious cycle phenomenon is interrupted by PGI2 and PGE1 treatment, resulting in a lower actual PGI2-formation in the activated cells, whereas the ones in the contractile cells is not affected at all. Similar findings can be obtained for the radioactive thin-layer chromatography of human femoral and popliteal artery tissue showing paralleling changes in the formation of 6-keto-PGF1α after both PGI2 and PGE1 therapy. The findings demonstrate that PGE1 and PGI2 have a significant antiproliferative and antimitotic action in experimental animals and in human as well. Platelet-derived growth factor is discussed as being the main pathogenetic factor balancing smooth muscle proliferation by either direct stimulation or inhibition through an increasing effect on vascular wall PGI2 synthesis. These findings firstly demonstrate in humans that proliferation of smooth muscle cells can be affected by prostaglandin therapy in clinically relevant doses.
Preview
Unable to display preview. Download preview PDF.
References
Aoyagi T, Suye H, Kato N, Nemoto O, Kobayashi H, Minva Y (1985) Epidermal growth factor stimulates release of arachidonic acid in pig epidermis. J Invest Dermatol 84: 168–171
Berberian PA, Ziboh VA, Hsia SL (1977) Inhibition of cholesterol esterification in rabbit aorta by prostaglandin E2. Atherosclerosis 27: 213–220
Bonchek LI, Boerboom LE, Olinger GN, Pepper JR, Munns J, Hutchinson L, Kissebah AH (1982) Prevention of lipid accumulation in experimental vein bypass grafts by antiplatelet therapy. Circulation 66: 338–341
Castor CW, Ritchie J, Scott ME (1977) Connective tissue activation and stimulation of glycosaminoglycan and DNA formation by platelet factor. Arch Pharm (Weinheim) 20: 859–868
Chait A, Ross R, Alberts H (1980) Platelet derived growth factor stimulates activity of low-density lipoprotein receptors. Proc Natl Acad Sci USA 77: 4084–4088
Coughlin SR, Moshkowitz MA, Antoniades HN (1981) Serotonin receptor mediated stimulation of bovine smooth muscle cell prostacyclin synthesis and its modulation by platelet derived growth factor. Proc Natl Acad Sci USA 78: 7134–7138
Dembinska-Kiec A; Rücker W, Schönhofer PS (1980) Effects of PGI2 and PGI2 analogues on cAMP levels in cultured endothelial and smooth muscle cells derived from bovine arteries. Naunyn Schmiedebergs Arch Pharmacol 311: 67–70
Dembinska-Kiec A, Gryglewski RJ (1986) Contribution of arachidonic acid metabolites to atherosclerosis. Wien Klin Wochenschr 98: 196–199
Fairbanks KP, Witte LD, Goodman DS (1986) Effects of platelet derived growth factor on 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Arteriosclerosis 6: 32–41
Feigl W, Sinzinger H, Wagner O, Leithner C (1975) Quantitative morphological investigations on smooth muscle cells in vascular surgical specimens and their clinical importance. Experientia 31: 1352–1353
Fleisher LN, Ton AN, Witte LD, Miller RN, Cannon RY (1982) Stimulation of arterial endothelial cell prostacyclin synthesis by high-density lipoproteins. J Biol Chem 257: 6653–6655
Fogelman AM, Shehter I, Seager J, Hokam M, Child JS, Edwards PA (1980) Malondialdehyde alteration at low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA 77: 2214–2218
Grotendorst GR, Seppa HEJ, Kleinman H, Martin H (1981) Attachment of smooth muscle cells to collagen and their migration toward plateled-derived growth factor. Proc Natl Acad Sci USA 78: 3669–3672
Habenicht AJR, Glomset JA, Ross R (1980) Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and swiss 3T3 cells stimulated to divide by platelet derived growth factor. J Biol Chem 255: 5134–5140
Hajjar DP, Weksler BB, Falcone DJ, Hefton JM, Tack-Goldman K, Minick CR (1982) Prostacyclin modulates cholesteryl ester hydrolytic activity by its effect on cyclic adenosine monophosphate in rabbit aortic smooth muscle cells. J Clin Invest 70: 479–488
Hajjar DP (1984) Prostaglandins modulate arterial cholesteryl ester metabolism. Enzyme 32: 218–227
Hajjar DP (1985) Prostaglandins and cyclic nucleotides. Modulators of arterial cholesterol metabolism. Biochem Pharmacol 34: 295–300
Hüttner II, Gwebu ET, Panganamala RV, Sharma HM, Geer JC (1977) Fatty acids and their prostaglandin derivatives: inhibitors of proliferation in aortic smooth muscle cells. Science 197: 289–291
E. A. Jaffe (1983) Production of PGI2 by cultured endothelial cells and smooth muscle cells. Circulation 86: 225.
Larrue J, Bricaud H, Sinzinger H (1984) Prostacyclin synthesis by proliferative aortic smooth muscle cells. Vasa 13: 311–318
Loesberg C, van Wijk R, Zandbergen J, van Aken WG, van Mourik JA, de Groot PG (1985) Cell cycle-dependent inhibition of human vascular smooth muscle cell proliferation by prostaglandin E2. Exp Cell Res 160: 117–125
McCaun RL, Hagen PO, Fuchs JCA (1980) Aspirin and dipiridamole decrease intimai hyperplasia in experimental vein grafts. Am Surg 191: 138
Metke MP, Lie JT, Fuster V, Josa M, Kaye MP (1979) Reduction of intimai thickening in canine coronary bypass vein grafts with dipyridamole and aspirin. Am J Cardiol 43: 1144–1148
Moncada S, Gryglewski RJ, Bunting S, Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663–665
Morita I (1983) Regulation of cell growth by prostaglandins. Gan To Kagaku Ryoho 10: 1919–1929
Nakao Y, Ooyama T, Chang WC (1982) Platelets stimulate aortic smooth muscle cell migration in vitro. Atherosclerosis 43: 143–150
Niewiarowski S, Paul D (1981) Platelet granule proteins with mitogenic and antiheparin activity. In: Gordon JL (ed) Platelets in biology and pathology/2. Elsevier, Amsterdam, pp 91–106
Pietila K, Moilanen T, Nikkari T (1980) Prostaglandins enhance the synthesis of glycosaminoglycans and inhibit the growth of rabbit aortic smooth muscle cells in culture. Artery 7: 509–518
Ross R; Glomset JA (1976) The pathogenesis of atherosclerosis. N Engl J Med 295: 268–377
R Ross (1981) The platelet-derived growth factor. Handbuch der experimentellen Pharmakologie, Vol 57: 133–159.
Sato Y, Hotta N, Sakamoto N, Matsuoko S, Ohishi N, Yagi K (1979) Lipid peroxide level in plasma of diabetic patients. Biochem Med 21: 104–108
Shimamoto T (1974) A new concept in atherogenesis and thrombogenesis and the treatment of atherosclerosis with an endothelial cell relaxant in cardiovascular disease. In: Russel HJ (ed) New concepts in diagnosis and therapy. Urban und Schwarzenberg, München, pp 361–392
Silberbauer K, Willvonseder R, Feigl W, Krisch K, Sinzinger H (1976) Morphologische und zellkinetische Untersuchungen an der Arterienwand nach Röntgenbestrahlung. Vasa 5: 215–219
Silberbauer K, Sinzinger H, Winter M (1978) Prostacyclin production by vascular smooth muscle cells. Lancet i: 1356–1357
Silberbauer K, Sinzinger H, Winter M (1979) Prostacyclin activity in rat kidney stimulated by angiotensin II. Br J Exp Pathol 60: 38–44
Sinzinger H, Willvonseder R, Feigl W, Wicke L, Höfer R, Hernuss P (1975) Einflüsse experimentell induzierter Streßsituation auf die Gefäßwand des Kaninchens. Z Mikrosk Anat Forsch 89: 257–263
Sinzinger H, Silberbauer K, Auerswald W (1980) Prostacyclin production by vascular smooth muscle and endothelial cells. Atherosclerosis V: 140–143
Sinzinger H, Kefalides A, Hoche C (1982) Is the platelet derived growth factor (PDGF) a main regulator in atherosclerosis? Circulation 66: 192
Sinzinger H, Fitscha P (1986) The principles and applications of treatment of atherosclerotic lesions with prostaglandins. Proc. Conf. on Radionucl. Label. Cell. Blood Elements, RSA Bloemfontein
Smith DL, Willis AL, Mahmud I (1984) Eicosanoid effects on cell proliferation in vitro: relevance to atherosclerosis. Prostaglandins Leukotrienes Med 16: 1–10
Subbiah MTR; Dicke BA (1977) Effect of prostaglandin E2 and F1α on the activities of cholesteryl ester synthetase and cholesteryl ester hydrolases of pigeon aorta in vitro. Atherosclerosis 27: 107–111
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Sinzinger, H. (1986). Inhibition of Mitotic and Proliferative Activity of Smooth Muscle Cells by Prostaglandin E1 . In: Sinzinger, H., Rogatti, W. (eds) Prostaglandin E1 in Atherosclerosis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71679-9_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-71679-9_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-17240-6
Online ISBN: 978-3-642-71679-9
eBook Packages: Springer Book Archive